The Next Web reports that Lightspeed Venture Partners led the round, with IVP, Premji Invest, and Lux Capital participating. Warp said the financing values the company at $865 million including the new capital.
Warp is targeting a drug-development step after researchers identify a promising molecule: making large numbers of molecular variants to improve properties and reduce side effects. The company says it is building a fully automated laboratory in the United States rather than discovering drugs itself. Its team is about 20 people and has bought robotic arms and AI chips.
The reported co-founders are Manohar Paluri, DJ Patil, and Solomon Reisberg. Warp plans to collect training data by having chemists use cameras and pressure-sensing gloves during experiments. The report does not establish that the laboratory is operating at production scale, that Warp's models outperform existing methods, or that it has pharmaceutical customers or disclosed timelines for delivery.